

Index

- AAH. *See* Atypical adenomatoid hyperplasia (AAH)
 ABC. *See* Active breathing control (ABC)
 Acinar pattern
 adenocarcinoma 18
 ACTH. *See* Adrenocorticotrophic hormones (ACTH)
 Active breathing control (ABC) 130
 Acute oesophagitis 122
 Adenocarcinoma 16–19
 acinar pattern 18
 air space opacification 35
 defined 18
 incidence 28
 mediastinal nodal metastases 66
 micropapillary pattern 19
 peripheral 137
 vs. squamous cell carcinoma
 brain metastases 76
 untreated
 natural history of 2
 Adenomas. *See* Adrenal adenomas
 Adenosquamous carcinoma 20
 Adjuvant carboplatin
 NSCLC 103
 Adjuvant chemotherapy
 NSCLC 103–6
 postoperative
 NSCLC 104
 Adjuvant cisplatin
 NSCLC 103
 Adjuvant paclitaxel
 NSCLC 103
 Adjuvant radiotherapy
 NSCLC 122–3
 Adjuvant uracil-tegafur
 NSCLC 103
 Adjuvant vinorelbine
 NSCLC 103
 Adrenal adenomas
 CT 74
 FDG-PET 74
 MRI 75
 Adrenal glands
 CT 73
 Adrenal metastases 74
 CT
 PET 89
 from benign incidental adrenal lesions 89
 staging 73–5
 Adrenocorticotrophic hormones (ACTH) 6
 Advanced-stage non-small cell lung cancer
 palliative chemotherapy 100–2
 Age
 radiation pneumonitis 121
 Air bronchograms 31
 bronchoalveolar cell carcinomas 40
 Air space opacification
 adenocarcinomas 35
 Airway caliber 38
 Alveolar walls
 atypical pneumocytes 14
 Antibiotics
 dose-intensification 110
 Antidiuretic hormone (ADH) 6
 Aorto-pulmonary nodes
 defined 67
 Apical tumours
 assessment 32
 PET 91
 Apoptosis rate
 small cell carcinoma 17
 Artefacts 95
 PET/CT 95
 Asbestos exposure
 occupational 2
 Atelectasis
 pulmonary 37
 Atypical adenomatoid hyperplasia (AAH) 13, 14
 Atypical pneumocytes
 lining alveolar walls 14
 BAC. *See* Bronchoalveolar cell carcinomas (BAC)
 Benign fibrous adhesion
 simulating tumour infiltration 71
 Benign incidental adrenal lesions
 adrenal metastases
 PET 89

144 Index

- Benign processes
 - 18FDG-PET 94
- Bevacizumab 111
 - NSCLC 108
- Biopsy
 - bronchial 7
 - image-guided percutaneous needle 137
- Bone metastases 4, 76–7
 - NSCLC 76
 - vertebral
 - PET 90
- Bone scanning
 - radionuclide
 - NSCLC 76
- Bortezomib
 - NSCLC 108
- Brain metastases 4
 - adenocarcinomas *vs.* squamous cell carcinoma 75
 - 18FDG-PET 94
 - radiotherapy 129
 - staging 76
- British Medical Research Council 111
- Bronchial biopsy 7
- Bronchial carcinomas
 - peripheral
 - shape 34
- Bronchial gland carcinoma 28
- Bronchial mucosa
 - CT 34
- Bronchial obstruction 37
- Bronchoalveolar cell carcinomas (BAC) 17, 28, 39–40
 - air bronchograms 40
 - CT 40
 - mucinous 18
 - non-mucinous 18
 - radiological presentations 40
 - surgery 140
- Bronchoceles 38
- Bronchogenic carcinoma
 - central *vs.* peripheral tumours 34
 - new cases of 27
 - prognostic factors 10
- Calcification
 - CT 35
 - intratumoural
 - CT 30
- Calcitonin 6
- Carboplatin
 - NSCLC 100–2, 104
 - adjuvant 103
 - SCLC 110, 111
- Carcinogens 2
- Carcinoid tumours 21–2
 - defined 21
 - histological features 21
- CAV. *See* Cyclophosphamide, adriamycin, vincristine (CAV)
- Cavitation
 - peripheral tumours 35
 - squamous cell cancer 35
- 11C-choline 96
- CD117 111
- Cell type 10
- Cell type-specific imaging patterns 38
- Centrally located tumours 15–16
- Central tumours
 - delineation 38
 - imaging 37
 - vs.* peripheral tumours 34–40
 - bronchogenic carcinoma 34
- Centrilobular emphysema 138
- Cetuximab
 - NSCLC 108
- CHART. *See* Continuous hyperfractionated accelerated radiotherapy (CHART) regime
- Chemotherapy
 - adjuvant
 - NSCLC 103–6
 - cytotoxic
 - NSCLC 99
 - SCLC 99
 - NSCLC 120
 - palliative
 - advanced-stage NSCLC 100–2
 - SCLC 109–11
- Chemotherapy radiotherapy combination
 - NSCLC 123
- Chest radiography 29–30, 38, 61
 - plain 29
 - pleural effusion 30
 - screening 47
 - vs.* CT 50
 - sensitivity 30
- Chest wall invasion
 - CT 32, 71
 - MRI 32
 - staging 71–2
- Chromogranin
 - large cell carcinoma 20
- Cigarettes
 - average consumption 12
 - problem awareness
- Cisplatin
 - NSCLC 100, 101, 104
 - adjuvant 103
 - SCLC 109
 - with irinotecan 110
- C-kit tyrosine kinase inhibitors 111
- Classification
 - small cell lung cancer 59
 - squamous cell cancer 15
- Clear cell carcinoma 28
- Clinical considerations 1–10
- Clinical features 3–6
- Clinical target volume (CTV) 127

- Collapse 37
- Computed tomography (CT) 6, 30–2, 51
 adrenal adenomas 74
 adrenal glands 73
 adrenal metastases
 angiogram
 enhancing pulmonary vessels radiating into left
 lower lobe 41
 artefacts 95
 bronchial mucosa 34
 bronchoalveolar cell carcinomas 40
 calcification 35
 vs. chest radiographs for screening 50
 chest wall invasion 71
 contrast-enhanced 61, 63
 vs. conventional planning
 SCLC 126
 cost-effectiveness 53
 data acquisition and planning 130
 enlarged mediastinal and hilar lymph nodes 31
 guided biopsy 7
 hilar mass 65
 intratumoural calcification 30
 liver 73
 lobectomy vs. pneumonectomy 62
 mediastinal lymph node status 70
 mediastinal staging 69
 vs. MRI
 chest wall invasion 32
 T4 tumours 64
 NSCLC 72, 90
 obstructive pneumonitis 69
 peripheral tumours 34
 vs. PET vs. EUS-FNA
 mediastinal metastases 70
 pulmonary nodule mis-registration 95
 respiratory motion 96
 respiratory shift 71
 screening 48
 optimism 49
 radiation from 53
 small cell carcinoma 39
 squamous carcinoma 138
 squamous cell carcinoma 71
 target volumes 127
 T4 squamous cell carcinoma 64
 T1 tumours 61
 upper lobe tumour 9
 volume 130
- Cone beam linear accelerators 126
- Conformal radiotherapy
 SCLC 126
- Consolidation 37
- Continuous hyperfractionated accelerated
 radiotherapy (CHART) regime 123
- Contrast-enhanced computed tomography 61
- Coronal MRI
 T1-weighted
 tumour at left apex 33
- Cost-effectiveness
 CT 53
 screening 50
- Cranial irradiation
 prophylactic 120
 SCLC 124–5
- CT. *See* Computed tomography (CT)
- CTV. *See* Clinical target volume (CTV)
- Cyclophosphamide, adriamycin, vincristine (CAV)
 LS-SCLC 109
 SCLC 109
- Cytotoxic agents
 SCLC 110–11
- Cytotoxic chemotherapy
 NSCLC 99
 SCLC 99
- Deaths 12, 27, 46
- Diagnosis 6
- Differentiated lung cancer
 untreated
 natural history of 2
- Digital radiographic technology 30
- Distant metastases
 NSCLC 73
 signs and symptoms 4
- Docetaxel
 NSCLC 100, 102
 with pemetrexed 102
 vs. platinum 102
- Dose-intensification
 antibiotics 110
 growth factors 110
 peripheral blood stem cell transplant 110
- Doubling time 36
- Early Lung Cancer Action Project (LECAP) 48
- ECOG 4599 study 108
- EGFR. *See* Epidermal growth factor receptor (EGFR)
- Electronic portal imaging device (EPID) 126
- ELVIS trial 102
- Emphysema
 centrilobular 138
- En bloc resection
 mortality rate 71
- Endobronchial airway
 videobronchoscopy 8
- Endobronchial radiotherapy
 intracavitary brachytherapy 129
- Endobronchial tumours 21–2
- Endo-oesophageal ultrasound with fine-needle
 aspiration (EUS-FNA) 69
- EPID. *See* Electronic portal imaging device (EPID)
- Epidermal growth factor receptor (EGFR) 111
 NSCLC 107–8
 overexpression
 squamous cell carcinomas 13
- ES-SCLC. *See* Extensive small cell lung cancer
 (ES-SCLC)

146 Index

- Etoposide
 NSCLC 104
 SCLC 109–11
 EURO CARE 10
 EUS-FNA. *See* Endo-oesophageal ultrasound with fine-needle aspiration (EUS-FNA)
 Extensive small cell lung cancer (ES-SCLC) 108
 prognosis 109
 Extrathoracic metastatic disease 73–7
- False negatives
 indeterminate solitary pulmonary nodules
 PET 86
 False positives 71
 18FDG-PET 94
 indeterminate solitary pulmonary nodules
 PET 86
 Farnesyl transferase inhibitors 111
 Fast helical scanners 40
 18F-fluormisonidazole
 tumour hypoxia 96
 18F-fluorothymidine (18FLT) 96
 Fiberoptic bronchoscopy 6–9
 Fibrosing lung diseases 137
 Fine needle aspiration
 transbronchial
 videobronchoscopy 8, 9
 18fluoro-2-deoxy-D-glucose (18FDG) 61
 half-life 86
 mesothelioma 94
 positron emission tomography (PET)
 adrenal adenomas 74
 assessing response to treatment 91–2
 benign processes increased uptake 94
 brain metastases 94
 diagnostic issues and pitfalls 94–6
 false positives 94
 future applications 96
 indeterminate solitary pulmonary nodules 86
 mesothelioma 94
 NSCLC 92, 93
 NSCLC IIIA-N2 92
 NSCLC staging 86
 planning radiotherapy 92
 radiotherapy response 92
 small cell lung cancer 94
 thoracic malignancies 93–4
 T4 squamous cell carcinoma 64
 tumour recurrence evaluation 93
 whole body 73
 right lower lobe 87
 solitary pulmonary nodule 85
 5-fluorouracil (5-FU) 103
 Focal pneumonia 4
 4D-CT data acquisition and planning 130
- Gastrin-releasing peptide 111
 Gemcitabine
 NSCLC 100
- Genetic alterations 13
 Glycolysis
 malignant tumours 86
 Golden's "S" sign 37, 38
 Gross tumour volume (GTV) 127
 Ground-glass haloes 31, 40, 138
 Growth factors
 dose-intensification 110
 Growth rate 3, 36
 GTV. *See* Gross tumour volume (GTV)
- Helical scanners
 fast 40
 Hepatic metastases 75
 Heterogeneity phenomenon
 mediastinal lymph nodes 68
 Highest mediastinal nodes
 defined 67
 Hilar disease
 peripheral carcinoma
 CT 88
 Hilar enlargement 37, 38
 Hilar mass 34
 CT 65
 Hilar nodes 66
 CT 31
 defined 67
 Histological features
 carcinoid tumours 21
 squamous cell cancer 15
 Histological subtypes 14–22
 Histopathological classification 27–8
 HOOA. *See* Hypertrophic pulmonary osteoarthropathy (HOOA)
 osteoarthropathy (HOOA)
 Horner's syndrome 4
 Hyperfractionation 123
 Hypertrophic pulmonary osteoarthropathy (HOOA)
 with digital clubbing 6
- IALT. *See* International Adjuvant Lung Cancer Collaborative Group (IALT)
 ICE (ifosfamide, carboplatin, etoposide)
 SCLC 110
 ICE-V (ifosfamide, carboplatin, etoposide, vincristine)
 SCLC 111
 ICRU. *See* International Commission on Radiation Units (ICRU)
 IDEAL trials 107–8
 Ifosfamide
 SCLC 110, 111
 IGRT. *See* Image guided radiotherapy techniques (IGRT)
 Image-guided percutaneous needle biopsy 137
 Image guided radiotherapy techniques (IGRT) 126
 Imaging ix, 27–41, 61–2
 cell type-specific patterns 38
 central tumours 37
 thoracic 57

- Immunohistochemical evaluation
 small cell lung cancer 16–9
- IMRT. *See* Intensity modulated radiation therapy (IMRT)
- Incidence 12
 adenocarcinoma 28
 females 1
 large cell carcinoma 28
 males 1
 small cell lung cancer 12
 squamous cell cancer 27
- Indeterminate solitary pulmonary nodules
 PET 86–7
 false negatives 86
 false positives 86
- Intensity modulated radiation therapy (IMRT)
 NSCLC 128–9
- Interlobar nodes
 defined 67
- Internal target volume (ITV) 128
- International Adjuvant Lung Cancer Collaborative Group (IALT) 103, 104
- International Commission on Radiation Units (ICRU)
 target volume definitions 127
- International Staging System for Lung Cancer
 57–9
- International Staging System for NSCLC 57
- Intracavitary brachytherapy
 endobronchial radiotherapy 129
- Intrathoracic extension 4
- Intratympanic calcification
 CT 30
- Irinotecan
 with cisplatin
 SCLC 110
 NSCLC 100
- ITV. *See* Internal target volume (ITV)
- Keratin pearl
 squamous cell cancer 16
- Kilovoltage attachment 126
 KVp 30
- Lambert-Eaton myasthenic syndrome 6
- Large cell carcinoma 19–20
 defined 19
 incidence 28
 neuroendocrine differentiation 20
 synaptophysin 20
- LECAP. *See* Early Lung Cancer Action Project (LECAP)
- Life time risk of cancer 1
- Limited small cell lung cancer (LS-SCLC) 108
 cyclophosphamide, adriamycin, vincristine 109
 prognosis 109
 radiotherapy 124–5
 survival 109
 topotecan 109
- Linear accelerator couch 125
- Liver
 CT 73
 NSCLC 75
- Lobar nodes
 defined 67
- Lobectomy
 vs. pneumonectomy
 CT 62
- Lower lobe carcinoma 93
- Lower paratracheal nodes
 defined 67
- LS-SCLC. *See* Limited small cell lung cancer (LS-SCLC)
- Lung cancer
 etiology 1–2
 global problem i
 multidisciplinary approach i
 untreated
 natural history of 2
- Lymph nodes. *See also* Mediastinal lymph nodes
 map definitions 67
 staging 58
- Magnetic resonance imaging (MRI) 32–3, 61
 adrenal adenomas 75
 vs. computed tomography
 chest wall invasion 32
 T4 tumours 64
 pericardial invasion 33
 respiratory shift 71
 staging nodal diseases 69
 T2-weighted 61
 T1-weighted coronal
 tumour at left apex 33
- Malignant tumours
 glycolysis 86
- Matrix metalloproteinase inhibitors 111
- Mayo CT screening study 48–9
- MDCT. *See* Multidetector row CT (MDCT)
- Mediastinal invasion 64–6
 radiological appearance 29
- Mediastinal lymph nodes 66–70
 CT 31, 70
 evaluating involvement 62
 heterogeneity phenomenon 68
 metastases
 adenocarcinoma 66
 CT vs. PET vs. EUS-FNA 70
 NSCLC 66
 PET 70
- Mediastinal staging 63–70
 CT 69
 NSCLC 88
- Mediastinal structures 65
- Megavoltage (MV) radiation 125
- Men
 life time risk of cancer 1
 lung cancer incidence in 1

148 Index

- Mesothelioma
 FDG 94
 18FDG-PET 94
- Metastases. *See also* Adrenal metastases
 bone 4, 76–7
 NSCLC 76
- brain
 adenocarcinomas *vs.* squamous cell carcinoma 76
 18FDG-PET 94
 radiotherapy 129
 staging 76
- distant
 NSCLC 73
 signs and symptoms 4
- extrathoracic 73–7
 hepatic 75
 occult 73
 radiotherapy 129
 squamous cell cancer 15
- Micropapillary pattern
 adenocarcinoma 19
- Mitomycin
 NSCLC 104
- Modern radiotherapy techniques
 SCLC 125–6
- Molecular alterations 13
- Mortality rate
 en bloc resection 71
- MRC LU21 trial 111
- MRI. *See* Magnetic resonance imaging (MRI)
- MRP. *See* Multiplanar reformats (MRPs)
- MTOR antagonists 111
- Multidetector row CT (MDCT) 65
 superior sulcus tumours 72
- Multidisciplinary approach xi
- Multiplanar reformats (MRPs) 65
- Multistep carcinogenesis theory 13
- MV. *See* Megavoltage (MV) radiation
- NATCH trial 106
- National Cancer Research Institute (NCRI)
 NSCLC 101
- National Institute for Health and Clinical Excellence (NICE)
 NSCLC 102
 chemotherapy 100
- Natural history 2–3
- NCRI. *See* National Cancer Research Institute (NCRI)
- Neo-adjuvant carboplatin
 NSCLC 106
- Neo-adjuvant chemotherapy
 NSCLC
 early-stage disease 106
- Neo-adjuvant paclitaxel
 NSCLC 106
- Neural-cellular adhesion molecule (NCAM)
 large cell carcinoma 20
- Neuroendocrine differentiation
 large cell carcinoma 20
- Neuropeptide 111
- NICE. *See* National Institute for Health and Clinical Excellence (NICE)
- Nodules
 evaluation of 50
 likelihood of malignancy 49
- Non-small cell lung cancer (NSCLC) 57
 adjuvant carboplatin 103
 adjuvant chemotherapy 103–6
 adjuvant cisplatin 103
 adjuvant paclitaxel 103
 adjuvant radiotherapy 122–3
 adjuvant uracil-tegafur (UFT) 103
 adjuvant vinorelbine 103
- advanced-stage
 palliative chemotherapy 100–2
- bevacizumab 108
- bone metastases 76
- bortezomib 108
- carboplatin 100–2, 104
- cetuximab 108
- chemotherapy 120
- chemotherapy radiotherapy combination 123
- cisplatin 100, 101, 104
- CT 31, 72
- cytotoxic chemotherapy 99
- distant metastases 73
- docetaxel 100, 102
- EGFR 107–8
- etoposide 104
- 18FDG-PET
 planning radiotherapy 92
 radiotherapy response 92
 tumour recurrence evaluation 93
- five year survival figures 60
- gemcitabine 100
- IIIA–N2
 18FDG-PET 92
- IMRT 128–9
- irinotecan 100
- left upper lobe 36
- liver lesions 75
- mediastinal metastases
 TBNA 70
- mediastinal nodal metastases 66
- mediastinal staging 88
- mitomycin 104
- NCRI 101
- neo-adjuvant carboplatin 106
- neo-adjuvant chemotherapy
 early-stage disease 106
- neo-adjuvant paclitaxel 106
- NICE 102
 chemotherapy 100
- novel agents 107111
- paclitaxel 100, 104
- palliative treatment 100–2
- PET/CT 90
- PET staging 87–90

- PET vs. bone scintigraphy 89
 phase II trials 122
 phase II trials 122
 platinum 100, 101
 postoperative adjuvant chemotherapy 104
 postoperative radiotherapy 121
 radical radiotherapy 121–2
 radionuclide bone scanning 76
 radiotherapy 121–3
 radiotherapy fractionation 122–4
 resectability 60
 stage definitions 60
 stage IB 106
 stage II 106
 stage IIIB 139
 staging 59
 18FDG-PET 86
 surgery 139
 survival 106
 systemic treatment 99–108
 complementing radiotherapy 100–2
 complementing surgery 100–2
 taxol 100
 taxotere 100, 102
 VEGFT 107
 vinblastine 104
 vindesine 104
 vinorelbine 100–2, 104
- Novel agents
 NSCLC 107–111
 Novel cytotoxic agents
 SCLC 110–11
 NSCLC. *See* Non-small cell lung cancer
- OAR. *See* Organs at risk (OAR)
 Obstructive pneumonitis
 CT 69
 Occult metastases 73
 Occupational asbestos exposure 2
 Occupational carcinogen exposure 12
 Oesophagitis
 acute 122
 Organs at risk (OAR) 121
 Oxytocin 6
- Paclitaxel
 NSCLC 100, 104
 adjuvant 103
 Painting 12
 Palliative chemotherapy
 advanced-stage NSCLC 100–2
 Palliative radiotherapy 129
 Palliative treatment
 NSCLC 100–2
 Pancoast tumours 29, 73
 assessment 32
 Paraaortic nodes
 defined 67
- Paraesophageal subcarinal nodes
 defined 67
 Para-neoplastic syndromes 5–6
 Parathyroid hormone 6
 Paratracheal nodes
 defined 67
 Pathology 12–22
 PCI. *See* Prophylactic cranial irradiation (PCI)
 Pemetrexed
 with docetaxel
 NSCLC 102
 Pericardial effusion 4
 Pericardial invasion
 MR 33
 Peripheral adenocarcinoma 137
 Peripheral blood stem cell transplant
 dose-intensification 110
 Peripheral bronchial carcinomas
 shape 34
 Peripheral carcinoma
 hilar disease
 CT 88
 macroscopic picture 17
 Peripheral lesions 7
 Peripheral squamous tumours 38
 Peripheral tumours
 cavitation 35
 vs. central tumours 34–40
 bronchogenic carcinoma 34
 CT 34
 Persistent pneumonia 38
 PET. *See* Positron emission tomography (PET)
 Phase II trials
 NSCLC 122
 Plain chest radiography 29
 Planning target volume (PTV) 127
 Platinum
 NSCLC 100, 101
 vs. docetaxel 102
 Pleural effusion 4
 chest radiography 30
 Pneumocytes
 atypical
 lining alveolar walls 14
 Pneumonectomy
 vs. lobectomy
 CT 62
 Pneumonia
 focal 4
 persistent 38
 recurrent 38
 segmental 4
 Pneumonitis
 obstructive
 CT 69
 radiation damage 121
 Polypoid exophytic tumour
 videobronchoscopy 8

150 Index

- Poorly differentiated lung cancer
 - untreated
 - natural history of 2
- PORT meta-analysis 121–4
- Positive mediastinal nodes
 - adverse prognostic factors associated with 66
- Positron
 - target volume definition 130
- Positron emission tomography (PET) 61, 84–97
 - adrenal metastases 89
 - advantages of 84
 - apical lung carcinoma 91
 - artefacts 95
 - vs. bone scintigraphy
 - NSCLC 89
 - vs. EUS-FNA
 - mediastinal metastases 70
 - mediastinal lymph node status 70
 - NSCLC 90
 - pulmonary nodule mis-registration 95
 - respiratory motion 96
 - staging
 - NSCLC 87–90
 - surgery 140
 - tracers 85
 - vertebral bone metastasis 90
 - whole body 73
- Postoperative adjuvant chemotherapy
 - NSCLC 104
- Postoperative radiotherapy
 - NSCLC 121
- Pre-invasive lesions 13–14
- Preoperative staging 137
- Prevascular and retrotracheal nodes
 - defined 67
- Prognosis 10
 - bronchogenic carcinoma 10
 - ES-SCLC 109
 - LS-SCLC 109
 - positive mediastinal nodes 66
 - SCLC 109
- Prophylactic cranial irradiation (PCI) 120
 - SCLC 124–5
- PTV. *See* Planning target volume (PTV)
- Public demand
 - for screening 50
- Pulmonary atelectasis 37
- Pulmonary disease co-morbidity 137
- Pulmonary ligament nodes
 - defined 67
- Pulmonary vessels
 - radiating into left lower lobe
 - CT angiogram 41
- Puncture bronchoscopes 9
- Radiation
 - CT screening 53
 - damage 121
 - dose escalation 123
- Radiation pneumonitis
 - age 121
 - damage 121
 - development 121
 - smoking 121
- Radiation tattoos 125
- Radical radiotherapy
 - NSCLC 121–2
- Radiography. *See also* Chest radiography
 - digital 30
 - erect PA frontal 29
- Radiological tests 29–33
- Radiologist
 - role 137
- Radionuclide bone scanning
 - NSCLC 76
- Radiotherapy 120–31
 - brain metastases 129
 - endobronchial
 - intracavitary brachytherapy 129
 - future developments 130
 - image guided 126
 - LS-SCLC 124–5
 - metastatic disease 129
 - NSCLC 121–3
 - adjuvant 122–3
 - intensity modulated 128–9
 - postoperative 121
 - palliative 129
 - radical
 - NSCLC 121–2
 - SCLC
 - 3D conformal 126
 - modern techniques 125–6
 - target volume definition 127–8
 - treatment verification 126–7
 - symptomatic metastatic disease 120
- Radiotherapy fractionation
 - NSCLC 122–4
- Radon 2
- Recurrent pneumonia 38
- Reducing mortality
 - screening 50
- Resectability
 - NSCLC 60
- Resection
 - success rate 136
- Respiration
 - movement with lung tumours
 - 130–1
- Respiratory motion
 - PET/CT 96
- Respiratory shift
 - CT 71
 - MR 71
- Retrotracheal nodes
 - defined 67

- Risk
 - life time 1
- Risk factor 1
- RMI
 - superior sulcus tumours 72
- Salivary gland like tumours 22
- Sarcomatoid carcinoma 20, 28
- SCC. *See* Squamous cell cancer (SCC)
- SCLC. *See* Small cell lung cancer (SCLC).
- Screening 46–53
 - chest radiography 47
 - conditions for 47
 - cost-effective 50
 - prior trials 47–8
 - public demand for 50
 - reducing mortality 50
 - smokers 51
- Segmental nodes
 - defined 67
- Segmental pneumonia 4
- Signs and symptoms
 - distant spread 4
- Small cell carcinoma
 - apoptosis rate 17
 - CT 39
 - keratin stain 17
- Small cell lung cancer (SCLC). 15–16 *See also* Limited
 - small cell lung cancer (LS-SCLC)
 - alternating drug regimens 109–10
 - CAV 109
 - chemotherapy 109–11
 - cisplatin 109
 - classification 59
 - combined 16
 - conventional *vs.* CT planning 126
 - cytotoxic chemotherapy 99
 - 3D conformal radiotherapy 126
 - defined 16
 - dose-intensification 110
 - etoposide 109
 - extensive 108
 - prognosis 109
 - 18FDG-PET 94
 - ICE 110
 - ICE-V 111
 - immunohistochemical evaluation 16–19
 - incidence 12
 - modern radiotherapy techniques 125–6
 - novel cytotoxic agents 110–11
 - prognosis 109
 - prophylactic cranial irradiation (PCI) 124–5
 - radiotherapy
 - target volume definition 127–8
 - treatment verification 126–7
 - spread 28
 - surgery 140
 - survival 109
 - systemic treatment 108–11
 - untreated
 - natural history of 2
- Smokers
 - screening 51
- Smoking 137
 - radiation pneumonitis 121
 - risk factor 1
 - survival 50
- Solitary pulmonary nodule. *See also* Indeterminate
 - solitary pulmonary nodules
 - 18FDG 85
- Spiculation 38
- Spiral CT 31
- Sputum 3
- Squamous carcinoma
 - CT 138
 - left lower lobe 64
- Squamous cell cancer (SCC) 12, 32
 - cavitation 35
 - classification 15
 - CT 71
 - differentiation 15
 - disease stage 15
 - histology 15
 - incidence 27
 - with intercellular bridges 16
 - keratin pearl 16
 - metastases 15
 - untreated
 - natural history of 2
- Squamous cell carcinoma
 - vs.* adenocarcinoma
 - brain metastases 76
 - CT 64
 - EGFR-overexpression 13
 - 18FDG-PET 64
- Squamous cell dysplasia
 - no basement membrane invasion 14
- Squamous dysplasia 13
- Stage definitions
 - NSCLC 60
- Stage IB NSCLC
 - survival 106
- Stage IIA tumors 59
- Stage IIB tumors 59
- Stage IIIB NSCLC
 - surgery 139
- Stage IIIB tumors 59
- Stage II NSCLC
 - survival 106
- Stage I tumors 59
- Stage IV tumors 59
- Staging 57–77
 - adrenal metastases 73–5
 - brain metastases 76
 - chest wall invasion 71–2
 - guidelines

152 Index

- Staging (cont.)
 - nodal diseases
 - MRI 69
 - NSCLC 59
 - preoperative 137
 - surgery 137
 - Standardised uptake value (SUV) 84, 87
 - Subaortic (aorto-pulmonary) nodes
 - defined 67
 - Subcarinal nodes
 - defined 67
 - Subsegmental nodes
 - defined 67
 - Superior sulcus 29
 - Superior sulcus tumours 72–3
 - MDCT 72
 - RMI 72
 - Superior vena cava (SVC) 4
 - syndrome 4
 - Surgeon
 - working with radiologist 136–7
 - Surgery 136–41
 - broncho-alveolar cell carcinoma 140
 - down-staging disease 138–9
 - PET 140
 - SCLC 140
 - stage IIIB NSCLC 139
 - staging 137
 - T1-3 N2MO SNCLC 139
 - trends 137–8
 - Surgical biopsy 52
 - Survival
 - LS-SCLC 109
 - NSCLC 60
 - smoking 50
 - stage IB NSCLC 106
 - stage II NSCLC 106
 - SUV. *See* Standardised uptake value (SUV)
 - SVC. *See* Superior vena cava (SVC)
 - Symptomatic metastatic disease
 - radiotherapy 120
 - Symptoms 3
 - Symptoms and signs 3–4
 - Synaptophysin
 - large cell carcinoma 20
 - Systemic treatment 99–113
 - NSCLC 99–108
 - complementing radiotherapy 100–2
 - complementing surgery 100–2
 - Target volume
 - CT scanning 127
 - definitions 127
 - ICRU 127
 - positron 130
 - Tattoos 125
 - Taxol
 - NSCLC 100
 - Taxotere
 - NSCLC 100, 102
 - TBNA. *See* Transbronchial fine needle aspiration (TBNA)
 - Team approach xi
 - Thoracic imaging 57
 - Thoracic malignancies
 - 18FDG-PET 93–4
 - 3D conformal radiotherapy
 - SCLC 126
 - 3D-CT volume 130
 - TNM 57, 59
 - lung cancer 58
 - nodal staging 58
 - T1-3 N2MO SNCLC
 - surgery 139
 - Topotecan
 - LS-SCLC 109
 - Tracers
 - PET 85
 - Tracheobronchial nodes 66
 - Transbronchial fine needle aspiration (TBNA) 8
 - NSCLC mediastinal metastases 70
 - videobronchoscopy 9
 - Treatment response
 - 18FDG-PET 91–2
 - T4 squamous cell carcinoma
 - CT 64
 - 18FDG-PET 64
 - T1 tumours
 - CT 61
 - T3 tumours
 - vs. T4 tumours 62
 - T4 tumours
 - CT vs. MRI 64
 - detection 62
 - vs. T3 tumours 62
 - Tumour hypoxia
 - 18F-fluormisonidazole 96
 - Tumours
 - average size of 2
 - defined 20
 - movement with respiration 130–1
 - T1-weighted coronal MRI
 - tumour at left apex 33
 - T2-weighted MRI 61
 - UFT. *See* Uracil-tegafur (UFT)
 - Ultrasmall superparamagnetic ironoxide nanoparticles (USPIO) 69
 - Ultrasound 33
 - Untreated lung cancer
 - natural history of 2
 - Upper lobe tumour
 - CT scan 9
 - Upper paratracheal nodes
 - defined 67

- Uracil-tegafur (UFT)
 - NSCLC 103
- USPIO. *See* Ultrasmall superparamagnetic ironoxide nanoparticles (USPIO)
- Vaccine therapy 111
- Vascular endothelial growth factor (VEGF)
 - antibody 108, 111
 - NSCLC 107
- Vertebral bone metastases
 - PET 90
- Video bronchoscopes 9
- Videobronchoscopy
 - endobronchial airway 8
 - polypoid exophytic tumour 8
 - submucosal lesion 8
 - transbronchial fine needle aspiration 9
- Vinblastine
 - NSCLC 104
- Vincristine
 - SCLC 111
- Vindesine
 - NSCLC 104
- Vinorelbine
 - adjuvant 103
 - NSCLC 100–4
- Volumetric analysis 36
- Volumetric growth analysis 37
- Weight loss 4
- Welding 12
- WHO classification 14
- Whole body
 - FDG-PET 73
 - PET 73
- Women
 - life time risk of cancer 1
 - lung cancer incidence in 1